论文部分内容阅读
Iq7611是天津市医药科学研究所研制的醌类成份放射增敏药物。其作用机理初步研究表明可降低细胞氧耗量,增加氧分压;又可降低癌细胞谷胱甘肽的含量,使癌细胞丧失或减少了对射线的防护能力。自1981年9月到1985年3月在我院使用Iq7611同时合并放射治疗肺癌病人30例,与对照组32例对照性观察,取得较好的近期疗效。
Iq7611 is an steroid-type radiosensitizer drug developed by the Tianjin Institute of Pharmaceutical Sciences. The preliminary study of its mechanism of action shows that it can reduce the oxygen consumption of cells and increase the partial pressure of oxygen; it can also reduce the content of glutathione in cancer cells, so that the cancer cells lose or reduce their protective ability against radiation. From September 1981 to March 1985, 30 patients with lung cancer were treated with Iq7611 combined with radiotherapy at the same time in our hospital. Compared with 32 patients in the control group, good results were obtained.